GlassScriptPhysician profile
Karen Freeman
NPI 1326420647
$8,268.23
in general payments reported to CMS, 2019-2025
24 companies · $1,756 in 2025
The $1,756 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,461 · 2022: $1,800 · 2023: $1,868 · 2024: $1,384 · 2025: $1,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,574 · Education: $433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,574.29 |
| Education | $432.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,064.61 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Alnylam Pharmaceuticals INC. | $1,126.65 | 2021-2025 | Amvuttra |
| Actelion Pharmaceuticals US, INC. | $1,095.27 | 2022-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $613.73 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $586.14 | 2021-2025 | Farxiga, Wainua, Lokelma |
| Impulse Dynamics (USA) INC. | $493.84 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.23 | 2021-2025 | Jardiance |
| Pfizer INC. | $306.21 | 2021-2025 | |
| Scpharmaceuticals INC. | $245.74 | 2023-2025 | |
| Vifor Pharma, INC. | $223.93 | 2021-2025 | Veltassa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $211.51 | 2023-2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $206.98 | 2022 | |
| Merck Sharp & Dohme LLC | $191.22 | 2021-2024 | Verquvo, Winrevair |
| Kestra Medical Technology Services, INC. | $136.90 | 2022-2024 | Assure Wcd |
| United Therapeutics Corporation | $74.23 | 2021-2025 | Tyvaso |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $62.76 | 2021 | |
| Abiomed | $48.75 | 2025 | |
| Novo Nordisk INC | $25.19 | 2025 | Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $25.10 | 2025 | Nexletol |
| Medtronic, INC. | $23.09 | 2023 | Linq II |
| Daiichi Sankyo INC. | $20.37 | 2023 | Injectafer |
| Bridgebio Pharma, INC. | $17.98 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $16.77 | 2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.